Illustration of SpaceOAR Hydrogel

SpaceOAR™ Hydrogel

ASTRO 2021 Industry Expert Theater


 
ASTRO logo

Watch the complete recording of ASTRO 2021 Industry Expert Theater:

How Hydrogel Spacing with SBRT, CT Visibility and Procedural Excellence will Impact the Future of Prostate Cancer Radiotherapy


 

 

 

MODERATOR

Brian J Davis

Brian J. Davis, MD, PhD

Professor of Radiation
Oncology, Rochester, MN


 

SPEAKERS

Michael J. Zelefsky, MD

SBRT for Prostate Cancer. Is There an Optimal Dose or Regimen?

Michael J. Zelefsky, MD

Professor of Radiation Oncology, Chief, Brachytherapy Services, Co-Leader GU Disease Management Team, Greenberg Chair of Prostate Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY


 
Sean Collins, MD

Rationale for Utilization of SpaceOAR Vue in Prostate SBRT Dose Escalation.

Sean Collins, MD

Associate Professor in Radiation Medicine, Director, CyberKnife Prostate Program, Member, Prostate Program, Georgetown University Hospital, Lombardi Cancer Center, Washington, DC


 
Marcio Fagundes, MD

Technical Recommendations to Achieving Consistent Rectal Spacer Placement Quality.

Marcio Fagundes, MD

Medical Director, Radiation Oncology, Medical Director, Photon Therapy, Miami Cancer Institute at Baptist, Health South Florida, Miami, FL


 
SpaceOAR Vue Hydrogel

Visibly Different

SpaceOAR Vue Hydrogel is the next-generation hydrogel spacer that offers enhanced visibility via CT scan1

 


 

 
SABRE logo

Please visit clinicaltrials.gov or email Boston Scientific at SABREStudy@bsci.com to learn more.


 

 

Get SpaceOAR Hydrogel

Become a certified applier.

CONNECT WITH A REP

Sign Up

Get exclusive updates and clincial data.

JOIN NOW

Clincial Education

Online. On demand. On topic.

VISIT EDUCARE


 

References

  1. Data on file with Boston Scientific.
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
SpaceOAR and SpaceOAR Vue Hydrogels are intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR and SpaceOAR Vue Hydrogels to reduce the radiation dose delivered to the anterior rectum.
SpaceOAR and SpaceOAR Vue Hydrogels contain polyethylene glycol (PEG). SpaceOAR Vue Hydrogel contains iodine.
Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.
As with any medical treatment, there are some risks involved with the use of SpaceOAR and SpaceOAR Vue Hydrogels. Potential complications associated with SpaceOAR and SpaceOAR Vue Hydrogels include, but are not limited to: pain associated with SpaceOAR and SpaceOAR Vue Hydrogels injection, pain or discomfort associated with SpaceOAR and SpaceOAR Vue Hydrogels, local inflammatory reactions, infection (including abscess), urinary retention, urgency, constipation (acute, chronic, or secondary to outlet perforation), rectal tenesmus/muscle spasm, mucosal damage, ulcers, fistula, perforation (including prostate, bladder, urethra, rectum), necrosis, allergic reaction (localized or more severe reaction, such as anaphylaxis), embolism (venous or arterial embolism is possible and may present outside of the pelvis, potentially impacting vital organs or extremities), syncope and bleeding. The occurrence of one or more of these complications may require treatment or surgical intervention. URO-989811-AB.
All images are the property of Boston Scientific. All trademarks are the property of their respective owners.
Top